JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

JNJ

227.55

+1.33%↑

ISRG

521.53

-0.83%↓

ABT

106.07

-1.49%↓

MDT

100.69

+0.19%↑

A

133.98

-1.27%↓

Search

Quanterix Corp

Aperta

SettoreSettore sanitario

6.74 0.9

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.3

Massimo

6.77

Metriche Chiave

By Trading Economics

Entrata

-3.5M

-34M

Vendite

16M

40M

Margine di Profitto

-83.479

Dipendenti

471

EBITDA

5.7M

-31M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+8.38% upside

Dividendi

By Dow Jones

Utili prossimi

16 mar 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

108M

346M

Apertura precedente

5.84

Chiusura precedente

6.74

Notizie sul Sentiment di mercato

By Acuity

50%

50%

148 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

Quanterix Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 gen 2026, 23:07 UTC

Utili

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 gen 2026, 21:27 UTC

Utili

Texas Instruments 4Q Sales Rise, Profit Falls

27 gen 2026, 23:55 UTC

Discorsi di Mercato

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 gen 2026, 23:47 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 gen 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 gen 2026, 23:39 UTC

Discorsi di Mercato

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 gen 2026, 23:20 UTC

Utili

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 gen 2026, 23:20 UTC

Utili

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 gen 2026, 23:19 UTC

Utili

SK Innovation Posts Net Loss for Second Consecutive Year

27 gen 2026, 23:19 UTC

Utili

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 gen 2026, 23:18 UTC

Utili

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 gen 2026, 23:18 UTC

Utili

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 gen 2026, 23:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

27 gen 2026, 23:11 UTC

Discorsi di Mercato

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 gen 2026, 23:07 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 gen 2026, 22:17 UTC

Discorsi di Mercato

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 gen 2026, 22:06 UTC

Utili

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 gen 2026, 21:51 UTC

Utili

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

27 gen 2026, 21:43 UTC

Utili

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 gen 2026, 21:41 UTC

Utili

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 gen 2026, 21:38 UTC

Utili

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 gen 2026, 21:32 UTC

Utili

Ampol: Modest Profit From F&I International in 2025

27 gen 2026, 21:32 UTC

Utili

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 gen 2026, 21:31 UTC

Utili

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 gen 2026, 21:31 UTC

Utili

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 gen 2026, 21:30 UTC

Utili

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 gen 2026, 21:29 UTC

Utili

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 gen 2026, 21:29 UTC

Utili

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 gen 2026, 21:28 UTC

Utili

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Confronto tra pari

Modifica del prezzo

Quanterix Corp Previsione

Obiettivo di Prezzo

By TipRanks

8.38% in crescita

Previsioni per 12 mesi

Media 7.5 USD  8.38%

Alto 8 USD

Basso 7 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Quanterix Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

2 ratings

0

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.34 / 6.015Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Bullish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

148 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat